-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FibroGen (NASDAQ:FGEN) Cut to "Hold" at StockNews.com
FibroGen (NASDAQ:FGEN) Cut to "Hold" at StockNews.com
StockNews.com lowered shares of FibroGen (NASDAQ:FGEN – Get Rating) from a buy rating to a hold rating in a report issued on Wednesday morning.
Separately, The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a sell rating for the company in a report on Tuesday, May 24th.
Get FibroGen alerts:FibroGen Stock Up 3.1 %
NASDAQ:FGEN opened at $14.49 on Wednesday. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91. The business's 50 day moving average is $11.81 and its two-hundred day moving average is $12.01.
FibroGen (NASDAQ:FGEN – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. The firm had revenue of $29.81 million during the quarter, compared to the consensus estimate of $36.15 million. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm's revenue was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.45) earnings per share. As a group, equities analysts expect that FibroGen will post -3 EPS for the current year.Institutional Trading of FibroGen
A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in shares of FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after purchasing an additional 2,621,494 shares during the period. Soleus Capital Management L.P. bought a new stake in FibroGen during the 4th quarter valued at $21,862,000. Federated Hermes Inc. boosted its position in FibroGen by 84.1% during the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. First Trust Advisors LP grew its stake in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock worth $74,978,000 after purchasing an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock valued at $10,274,000 after purchasing an additional 748,230 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com lowered shares of FibroGen (NASDAQ:FGEN – Get Rating) from a buy rating to a hold rating in a report issued on Wednesday morning.
在周三上午发布的一份报告中，斯托克新闻网将FibroGen(纳斯达克代码：FDEN-GET)的股票评级从买入下调至持有。
Separately, The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a sell rating for the company in a report on Tuesday, May 24th.
另外，高盛夫妇在5月24日周二的一份报告中将FibroGen的目标价从9.00美元下调至8.00美元，并为该公司设定了卖出评级。
FibroGen Stock Up 3.1 %
FibroGen股价上涨3.1%
NASDAQ:FGEN opened at $14.49 on Wednesday. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91. The business's 50 day moving average is $11.81 and its two-hundred day moving average is $12.01.
纳斯达克：fgen周三开盘报14.49美元。FibroGen的52周低点为7.81美元，52周高位为16.91美元。该业务的50日移动均线切入位为11.81美元，200日移动均线切入位为12.01美元。
Institutional Trading of FibroGen
FibroGen的机构交易
A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in shares of FibroGen by 235.9% in the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock valued at $52,630,000 after purchasing an additional 2,621,494 shares during the period. Soleus Capital Management L.P. bought a new stake in FibroGen during the 4th quarter valued at $21,862,000. Federated Hermes Inc. boosted its position in FibroGen by 84.1% during the 1st quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. First Trust Advisors LP grew its stake in shares of FibroGen by 24.8% in the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company's stock worth $74,978,000 after purchasing an additional 1,055,536 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of FibroGen by 333.0% during the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company's stock valued at $10,274,000 after purchasing an additional 748,230 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
一些大型投资者最近调整了对该公司的持股。Point72 Asset Management L.P.在第四季度增持了235.9%的FibroGen股票。Point72 Asset Management L.P.在此期间额外购买了2,621,494股，现在拥有这家生物制药公司3,732,594股股票，价值52,630,000美元。Soleus Capital Management L.P.在第四季度购买了FibroGen的新股份，价值21,862,000美元。联合爱马仕公司在第一季度将其在FibroGen的头寸增加了84.1%。联合爱马仕公司目前持有这家生物制药公司2,395,883股股票，价值28,799,000美元，在此期间又收购了1,094,403股。First Trust Advisors LP在第四季度增持了24.8%的FibroGen股票。First Trust Advisors LP现在拥有这家生物制药公司5,317,613股股票，价值74,978,000美元，上个季度又购买了1,055,536股。最后，Assenagon Asset Management S.A.在第二季度增持了333.0%的FibroGen股票。Assenagon Asset Management S.A.在此期间又购买了748,230股票，现在拥有972,901股这家生物制药公司的股票，价值10,274,000美元。机构投资者和对冲基金持有该公司77.35%的股票。
About FibroGen
关于FibroGen
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物制药公司，发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat，该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发，并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 值得关注的两场重要的零售股大战
- MarketBeat：回顾中的一周2012-8-8
- 什么是WallStreetBets，他们的目标是什么股票？
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗？
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧